234 related articles for article (PubMed ID: 15876745)
1. [Bisphosphonates: the molecular targets and mechanisms of action].
Wada S; Kamiya S; Ono K
Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates: from bench to bedside.
Russell RG
Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and molecular mechanisms of action of bisphosphonates.
Rogers MJ; Crockett JC; Coxon FP; Mönkkönen J
Bone; 2011 Jul; 49(1):34-41. PubMed ID: 21111853
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the chemistry and biological activity of the bisphosphonates.
Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
[TBL] [Abstract][Full Text] [Related]
10. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
11. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates: preclinical review.
Green JR
Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
17. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
18. [Bisphosphonates and adhesion molecules].
Takeyama S; Shinoda H
Clin Calcium; 2002 May; 12(5):627-30. PubMed ID: 15775348
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
Li B; Ling Chau JF; Wang X; Leong WF
J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
